J. Nowak

Anti‐IL21 receptor monoclonal antibody (ATR‐107): Safety, pharmacokinetics, and pharmacodynamic evaluation in healthy volunteers: A phase I, first‐in‐human study

G. Comer, John B. Cheng, F. Hua, 2014, Journal of clinical pharmacology.

Assessment of clinical immunogenicity of inotuzumab ozogamicin in patients with non-Hodgkin lymphoma and acute lymphoblastic leukemia

J. Boni, B. Gorovits, D. Jani, 2018, AAPS Open.

Acute primary human immunodeficiency virus type 1 infection in a patient with concomitant cytomegalovirus encephalitis.

D. Berger, P. Gomatos, J. Nowak, 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Blood Serum Antibody Analysis and Long-Term Follow-up of Patients Treated With Recombinant Human Bone Morphogenetic Protein-2 in the Lumbar Spine

S. Glassman, J. Burkus, M. Gornet, 2011, Spine.

The delayed-type hypersensitivity reaction is dependent on IL-8. Inhibition of a tuberculin skin reaction by an anti-IL-8 monoclonal antibody.

B. Gesser, M. Deleuran, H. Thomsen, 1995, Journal of immunology.

Contribution of enhanced engagement of antigen presentation machinery to the clinical immunogenicity of a human interleukin (IL)‐21 receptor‐blocking therapeutic antibody

T. Hickling, L. Xue, R. Song, 2016, Clinical and experimental immunology.

Assessment of clinical immunogenicity of inotuzumab ozogamicin in patients with non-Hodgkin lymphoma and acute lymphoblastic leukemia

J. Boni, B. Gorovits, D. Jani, 2018 .

Blood Serum Antibody Analysis and Long-Term Follow-up of Patients Treated With Recombinant Human Bone Morphogenetic Protein-2 in the Lumbar Spine

S. Glassman, J. Burkus, M. Gornet, 2011, Spine.

A highly restricted antigen for renal cell carcinoma defined by a monoclonal antibody.

R. Vessella, P. Lange, J. Nowak, 1985, Hybridoma.